These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 1906351

  • 41. Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains, in a hamster pulmonary embolism model.
    Collen D, Lijnen HR, Vanlinthout I, Kieckens L, Nelles L, Stassen JM.
    Thromb Haemost; 1991 Feb 12; 65(2):174-80. PubMed ID: 1905070
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. Biochemical properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin.
    Dewerchin M, Lijnen HR, Van Hoef B, De Cock F, Collen D.
    Eur J Biochem; 1989 Oct 20; 185(1):141-9. PubMed ID: 2530085
    [Abstract] [Full Text] [Related]

  • 44. Biochemical properties of recombinant single-chain urokinase-type plasminogen activator mutants with deletion of Asn2 through Phe157 and/or substitution of Cys279 with Ala.
    Lijnen HR, Li XK, Nelles L, Hu MH, Collen D.
    Eur J Biochem; 1992 Apr 15; 205(2):701-9. PubMed ID: 1533368
    [Abstract] [Full Text] [Related]

  • 45. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
    Watahiki Y, Scully MF, Ellis V, Kakkar VV.
    Thromb Haemost; 1989 Jun 30; 61(3):502-6. PubMed ID: 2508259
    [Abstract] [Full Text] [Related]

  • 46. Structural and functional characterization of mutants of recombinant single-chain urokinase-type plasminogen activator obtained by site-specific mutagenesis of Lys158, Ile159 and Ile160.
    Lijnen HR, Nelles L, Van Hoef B, Demarsin E, Collen D.
    Eur J Biochem; 1988 Nov 15; 177(3):575-82. PubMed ID: 2973984
    [Abstract] [Full Text] [Related]

  • 47. Biochemical characterization of single-chain chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody and single-chain urokinase.
    Holvoet P, Laroche Y, Lijnen HR, Van Hoef B, Brouwers E, De Cock F, Lauwereys M, Gansemans Y, Collen D.
    Eur J Biochem; 1992 Dec 15; 210(3):945-52. PubMed ID: 1483477
    [Abstract] [Full Text] [Related]

  • 48. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G, Pascucci C, Nenci GG, Mele A, Bürgi R, Heim J.
    Thromb Haemost; 1993 Aug 02; 70(2):294-300. PubMed ID: 8236138
    [Abstract] [Full Text] [Related]

  • 49. Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction.
    Van de Werf F, Vanhaecke J, de Geest H, Verstraete M, Collen D.
    Circulation; 1986 Nov 02; 74(5):1066-70. PubMed ID: 2429783
    [Abstract] [Full Text] [Related]

  • 50. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
    Collen D, Stassen JM, Yasuda T, Refino C, Paoni N, Keyt B, Roskams T, Guerrero JL, Lijnen HR, Gold HK.
    Thromb Haemost; 1994 Jul 02; 72(1):98-104. PubMed ID: 7974384
    [Abstract] [Full Text] [Related]

  • 51. Effect of standard heparin and a low molecular weight heparin on thrombolytic and fibrinolytic activity of single-chain urokinase plasminogen activator in vitro.
    Lourenço DM, Dosne AM, Kher A, Samama M.
    Thromb Haemost; 1989 Nov 24; 62(3):923-6. PubMed ID: 2556812
    [Abstract] [Full Text] [Related]

  • 52. Biochemical and thrombolytic properties of a low molecular weight form (comprising Leu144 through Leu411) of recombinant single-chain urokinase-type plasminogen activator.
    Lijnen HR, Nelles L, Holmes WE, Collen D.
    J Biol Chem; 1988 Apr 25; 263(12):5594-8. PubMed ID: 2965704
    [Abstract] [Full Text] [Related]

  • 53. Comparison of thrombolytic, fibrinolytic, and fibrinogenolytic properties of tissue plasminogen activator, streptokinase, single-chain urokinase, high molecular weight and low molecular weight urokinase in human plasma in vitro.
    Samama M, Nguyen G, Desnoyers P, Lourenco DM, Fretault J, Horellou MH, Conard J, Szwarcer E, Verdy E, Vahanian A.
    Fundam Clin Pharmacol; 1988 Apr 25; 2(6):509-23. PubMed ID: 3149257
    [Abstract] [Full Text] [Related]

  • 54. Characterization of a recombinant chimeric plasminogen activator with enhanced fibrin binding.
    Jiao J, Yu M, Ru B.
    Biochim Biophys Acta; 2001 Apr 07; 1546(2):399-405. PubMed ID: 11295444
    [Abstract] [Full Text] [Related]

  • 55. [Development of new thrombolytic substances].
    Zeymer U, Neuhaus KL.
    Herz; 1994 Dec 07; 19(6):314-25. PubMed ID: 7843688
    [Abstract] [Full Text] [Related]

  • 56. Thrombolytic effects of tissue-type and urokinase-type plasminogen activators in rabbits with experimental pulmonary thromboembolization.
    Rahman F.
    Fukuoka Igaku Zasshi; 1990 Sep 07; 81(9):303-12. PubMed ID: 2125971
    [Abstract] [Full Text] [Related]

  • 57. Plasminogen activation with single-chain urokinase-type plasminogen activator (scu-PA). Studies with active site mutagenized plasminogen (Ser740----Ala) and plasmin-resistant scu-PA (Lys158----Glu).
    Lijnen HR, Van Hoef B, Nelles L, Collen D.
    J Biol Chem; 1990 Mar 25; 265(9):5232-6. PubMed ID: 1969415
    [Abstract] [Full Text] [Related]

  • 58. Intravenous thrombolytic therapy with a combination of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator in acute myocardial infarction.
    Bode C, Schuler G, Nordt T, Schönermark S, Baumann H, Richardt G, Dietz R, Gurewich V, Kübler W.
    Circulation; 1990 Mar 25; 81(3):907-13. PubMed ID: 2106403
    [Abstract] [Full Text] [Related]

  • 59. Thrombolytic properties of a novel modified human tissue-type plasminogen activator (E6010): a bolus injection of E6010 has equivalent potency of lysing young and aged canine coronary thrombi.
    Suzuki S, Saito M, Suzuki N, Kato H, Nagaoka N, Yoshitake S, Mizuo H, Yuzuriha T, Yui Y, Kawai C.
    J Cardiovasc Pharmacol; 1991 May 25; 17(5):738-46. PubMed ID: 1713988
    [Abstract] [Full Text] [Related]

  • 60. Fibrin-specific thrombolytic agents.
    Collen D.
    Schweiz Med Wochenschr; 1987 Nov 14; 117(46):1791-8. PubMed ID: 3122317
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.